twistbioscience.com (TWST): Operating Profitability

Corporate company logo of Twist Bioscience Inc (TWST)

Twist Bioscience (TWST) is actively expanding its commercial presence in the genomics and digital archives segment. Operating profitability allows for an assessment of this growth, where the value of -28.80 expresses the metric level. The company dominates DNA synthesis on chips by investing in bioengineering. The use of silicon technologies enables mass production at low costs, creating value for the medical and agricultural sectors.

TWST: twistbioscience.com Operating Sales Margin 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Twist Bioscience, Inc. (TWST)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Comprehensive company analysis:TWST, Twist Bioscience Corp
Brand item of twistbioscience.com

Long-term investing requires strict control over cost management efficiency. The specifics of Twist Bioscience (TWST) lie in the balance between stable demand for synthetic DNA and capital-intensive developments in data storage. By analyzing changes in the operating margin, an investor assesses the share of profit from core operations before taxes and interest. This indicator measures the business's ability to convert revenue into operating income. Positive dynamics would confirm the model's resilience to high R&D expenses.

Competitor analysis

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability